drugset / Trial / NCT01732445

Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis

NCT01732445

NaSingle-groupOpen-labelSupportive care

Summary

This phase II pilot trial studies how well ruxolitinib phosphate and danazol work in treating anemia in patients with myelofibrosis. Ruxolitinib phosphate and danazol may cause the body to make more red blood cells. They are used to treat anemia in patients with myelofibrosis.

Timeline

Start
2013-04
Primary completion
2016-07-14
Completion
2017-08-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Danazol Other / unclassified Oral
Subject Ruxolitinib Small molecule Oral